Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 5, Number 1—February 1999


Using Monoclonal Antibodies to Prevent Mucosal Transmission of Epidemic Infectious Diseases

Larry Zeitlin*, Richard A. Cone*†, and Kevin J. Whaley*†Comments to Author 
Author affiliations: *ReProtect, LLC, Baltimore, Maryland, USA; †The Johns Hopkins University, Baltimore, Maryland, USA

Main Article

Table 2

Examples of highly effective topical passive immunization of mucosa

Pathogen Speciesa Routeb Anti-bodyc Prevention Ref.
Herpes simplex mou v m 100% (64, 65)
r m 100% (66)
Influenza fer o p 100% (67)
mou n p > 4d (68)
Rotavirus hum o p 100% (69, 70)
Respiratory syncytial mon n m 3-4d (71)
Chlamydia trachomatis mou v m 90% (72)
Clostridium difficule ham o p 100% (73)
Escherichia coli hum o p 100% (74)
Porphyromonas gingivalis hum o m 100% (75)
Shigella flexneri hum o p 100% (76)
Staphylococcus aureus mou n p 3-4e (77)
Streptococcus mutans hum o m 100% (78)
Vibrio cholerae mou o m 100% (79)
Candida albicans mou v p >50f (80)
Cryptosporidium parvum mou o m 77g (81)

aSpecies tested in: mou=mouse; fer=ferret; hum=human; mon=monkey; ham=hamster.
bDelivery route of pathogen and antibody: v=vaginal; r=rectal; o=oral; n=nasal.
cAntibody: m=monoclonal; p=polyclonal.
d log10 reduction in virus titer.
e log10 reduction in cfu.
f % reduction in cfu.
g % reduction in number of parasites.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO